Sinopsis
MediCom Oncology Clinical Pearl Podcasts provide practical, evidence-based recommendations on real-world issues in the clinical setting, in under three minutes. Leading experts and academic faculty from top research and practice institutions provide guidance to community-based healthcare providers, including oncologists, pharmacists and nurses. Podcasts are brought to you by MediCom Worldwide, Inc., an accredited, independent medical education company.Podcasts are intended for licensed adult healthcare professionals (HCPs). HCPs should exercise professional judgment in evaluating content, and confirm information before implementing treatment or practice-related changes. Podcasts do not provide medical advice to patients.
Episodios
-
![How do I dose daratumumab, lenalidomide and dexamethasone in the combination regimen?]()
How do I dose daratumumab, lenalidomide and dexamethasone in the combination regimen?
27/09/2017 Duración: 01minIn under two minutes, Dr. Carol Ann Huff will discuss how to dose daratumumab in conjunction with lenalidomide and dexamethasone in patients with multiple myeloma.
-
![Is there a connection between pancreatic cancer and new-onset diabetes?]()
Is there a connection between pancreatic cancer and new-onset diabetes?
18/08/2017 Duración: 08minDr. Anil Rustgi discusses a clinical prediction model to assess risk for pancreatic cancer among patients with new-onset diabetes.
-
![CPX versus 7 and 3 conventional chemotherapy in older adults with AML]()
CPX versus 7 and 3 conventional chemotherapy in older adults with AML
18/08/2017 Duración: 03minDr. Stuart Goldberg briefly summarizes updates on CPX-351, a liposomal form of cytarabine and daunorubicin that allows for office infusion vs. standard consolidation requiring hospitalization.
-
![How long should I be infusing carfilzomib intravenously?]()
How long should I be infusing carfilzomib intravenously?
18/08/2017 Duración: 02minListen as Dr. Huff discusses the infusion duration for carfilzomib in patients with multiple myeloma.
-
![What is the current status of immunotherapy in pancreatic cancer?]()
What is the current status of immunotherapy in pancreatic cancer?
02/08/2017 Duración: 04minListen as Dr. O'Reilly discusses the the current status of immunotherapy in pancreatic cancer.
-
![Measuring Frailty in Patients Being Treated for Multiple Myeloma]()
Measuring Frailty in Patients Being Treated for Multiple Myeloma
02/08/2017 Duración: 01minListen for just under two minutes as Dr. Harvey explains measuring frailty in patients being treated for multiple myeloma.
-
![Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant IDH2]()
Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant IDH2
02/08/2017 Duración: 04minDr. Eytan Stein provides a brief update on patients experiencing differentiation syndrome in a larger enasidenib trial, detailing the creation of a Differentiation Syndrome Review Committee.
-
![How do I dose daratumumab, bortezomib and dexamethasone in the combination regimen?]()
How do I dose daratumumab, bortezomib and dexamethasone in the combination regimen?
02/08/2017 Duración: 03minListen as Dr. Carol Ann Huff discusses how to dose daratumumab, bortezomib and dexamethasone in the combination regimen.
-
![Update on the CALGB-100104 (Alliance) randomized trial]()
Update on the CALGB-100104 (Alliance) randomized trial
02/08/2017 Duración: 03minListen as Dr. Philip McCarthy provides an update on the CALGB-100104 (Alliance) randomized trial.
-
![How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy?]()
How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy?
02/08/2017 Duración: 01minListen as Dr. Alison Moskowitz discusses the difference between the safety profile of the new and emerging anti-PD-1 antibodies and chemotherapy.
-
![How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy?]()
How does the safety profile of the new and emerging anti-PD 1 antibodies differ from chemotherapy?
12/07/2017 Duración: 01minListen as Dr. Alison Moskowitz discusses the safety profile of the new and emerging anti-PD1 antibodies and how this differs from traditional chemotherapy in just under two minutes.
-
![ELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MM]()
ELOQUENT-2 updates represent the longest median FU of an immuno-oncology agent in MM
12/07/2017 Duración: 01minDr. Sagar Lonial provides a brief update on the ELOQUENT-2 phase 3 trial and how it continues to demonstrate a benefit in terms of progression-free survival.
-
![Optimal Pre-medication Strategy for Daratumumab]()
Optimal Pre-medication Strategy for Daratumumab
12/07/2017 Duración: 02minListen for just under two minutes as Dr. Harvey discusses optimal pre-medications for daratumumab, including H1 antagonists.
-
![Rash Management for Patients Taking IRd (Ixazomib-Lenalidomide-Dexamethasone)]()
Rash Management for Patients Taking IRd (Ixazomib-Lenalidomide-Dexamethasone)
29/06/2017 Duración: 01minListen as Dr. Harvey will discuss rash management for patients taking IRd.
-
![What is the appropriate management for severe hypercalcemia?]()
What is the appropriate management for severe hypercalcemia?
29/06/2017 Duración: 02minListen as Dr. Niesvizky explains the appropriate management for severe hypercalcemia.
-
![What is the most common cause of renal failure in newly diagnosed patients with multiple myeloma?]()
What is the most common cause of renal failure in newly diagnosed patients with multiple myeloma?
29/06/2017 Duración: 01minListen as Dr. Niesvizky discusses the most common cause of renal failure in newly diagnosed patients with MM.
-
![Standard dosing and delivery of Nal-IRI + 5-FU/LV]()
Standard dosing and delivery of Nal-IRI + 5-FU/LV
29/06/2017 Duración: 02minListen as Dr. Wang-Gillam discusses the standard dosing and delivery of Nal-IRI + 5-FU/LV.
-
![How important is the availability of supportive care when considering transplant in older patients?]()
How important is the availability of supportive care when considering transplant in older patients?
15/05/2017 Duración: 02minListen as Dr. Ritchie discusses the importance of available supportive care when considering transplant in older patients with MDS.
-
![Is the AE profile of BV the same or different from traditional monoclonal antibody therapies?]()
Is the AE profile of BV the same or different from traditional monoclonal antibody therapies?
15/05/2017 Duración: 02minListen as Dr. Moskowitz discusses the AE profile of BV and traditional monoclonal antibody therapies.
-
![When do you need to do a bone marrow biopsy in the management or assessment of multiple myeloma?]()
When do you need to do a bone marrow biopsy in the management or assessment of multiple myeloma?
15/05/2017 Duración: 02minListen as Dr. Richter discusses when you need to do a bone marrow biopsy in the management or assessment of multiple myeloma.
